5 Off-the-Radar Numbers to Take Note of in Johnson & Johnson's Second-Quarter Report
It's officially earnings season, which can only mean one thing: Johnson & Johnson (NYSE: JNJ) is kicking things off for big pharmaceutical companies.
On Tuesday morning, July 18, Johnson & Johnson released its second-quarter earnings results, keeping alive a recent trend of better-than-expected profits and lower-than-anticipated sales.
For the quarter, J&J, as the company is more commonly known, reported $18.84 billion in worldwide sales, which was a 1.9% increase from the prior-year quarter, or a 2.9% increase if we look at things on an apples-to-apples basis without currency fluctuations. By comparison, Wall Street had been looking for the company to deliver $18.97 billion in sales.
Source: Fool.com
Pfizer Inc. Stock
€25.77
0.140%
With 30 Buy predictions and 4 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of 41 € there is a hugely positive potential of 59.1% for Pfizer Inc. compared to the current price of 25.77 €.
